Abstract

Patients with drug-resistant tuberculosis (DR-TB) must undergo a heavy and prolonged treatment, which increases the chances of them defaulting on their medication. Family support is considered to help patients boost their treatment motivation. This study aims to examine the tendency of family support towards the healing beliefs of patients with drug-resistant tuberculosis (TB RO). This is a cross-sectional study involving 50 patients with TB RO in the Special Region of Yogyakarta from 2016 to 2020, utilizing a research instrument in the form of a questionnaire. Patients with good family support tend to be confident in their recovery (84%), while 44% of patients with less family support are uncertain about their recovery. Family support may influence patients' recovery beliefs, depending on the emotional conditions they experience.

There is no Figure or data content available for this article

References

• N. Ndjeka et al., “High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen,” Eur. Respir. J., vol. 52, no. 6, pp. 1–9, 2018, doi: 10.1183/13993003.01528-2018.
• Dirjen PPPL Kemenkes RI, “Tuberkulosis Multi-Drug Resistant,” Kementrian Kesehatan Republik Indonesia, 2019. https://www.tbindonesia.or.id/page/view/22/tb-mdr (accessed May 18, 2020).
• Kementrian Kesehatan RI, Petunjuk Teknis Manajemen Terpadu Pengendalian Resistan Obat. 2014.
• Z. Udwadia and J. Furin, “Quality of drug-resistant tuberculosis care: Gaps and solutions,” J. Clin. Tuberc. Other Mycobact. Dis., vol. 16, p. 100101, 2019, doi: 10.1016/j.jctube.2019.100101.
• C. Gugssa Boru, T. Shimels, and A. I. Bilal, “Factors contributing to non-adherence with treatment among TB patients in Sodo Woreda, Gurage Zone, Southern Ethiopia: A qualitative study,” J. Infect. Public Health, vol. 10, no. 5, pp. 527–533, 2017, doi: 10.1016/j.jiph.2016.11.018.
• T. Sukartini, I. Minarni, and C. P. Asmoro, “Family Support, Self-efficacy, Motivation, and Treatment Adherence in Multidrug-resistant Tuberculosis Patients,” Int. Nurs. Conf., no. Inc, pp. 178–182, 2019, doi: 10.5220/0008322301780182.
• L. Muna and U. Soleha, “Motivasi dan dukungan sosial keluarga mempengaruhi kepatuhan berobat pada pasien TB Paru,” J. Ilm. Kesehatan2, vol. 7, no. 2, pp. 172–179, 14AD.
• B. Chen et al., “Social support received by multidrug-resistant tuberculosis patients and related factors: A cross-sectional study in Zhejiang Province, People’s Republic of China,” Patient Prefer. Adherence, vol. 10, pp. 1063–1070, 2016, doi: 10.2147/PPA.S105655.
• R. Bhalavat, “Why Family Support is Crucial for The Recovery Process,” Maryland Recovery, 2016. .
• V. Peddireddy, “Quality of Life , Psychological Interventions and Treatment Outcome in Tuberculosis Patients?: The Indian Scenario Psychological Distress in Tuberculosis,” vol. 7, no. October, pp. 1–9, 2016, doi: 10.3389/fpsyg.2016.01664.
• A. A. Roba et al., “Tuberculosis patients are physically challenged and socially isolated: A mixed methods case-control study of Health Related Quality of Life in Eastern Ethiopia.,” PLoS One, vol. 13, no. 10, p. e0204697, 2018, doi: 10.1371/journal.pone.0204697.
• O. Oladimeji et al., “Clients’ Perception of Quality of Multidrug-Resistant Tuberculosis Treatment and Care in Resource-Limited Setting: Experience from Nigeria Olanrewaju,” Mycobacterium- Res. Dev., p. 13, 2016, doi: http://dx.doi.org/10.5772/57353.
• T. W. Yang et al., “Side effects associated with the treatment of multidrug-resistant tuberculosis at a tuberculosis referral hospital in South Korea,” Med. (United States), vol. 96, no. 28, 2017, doi: 10.1097/MD.0000000000007482.
• S. Khanal, H. Elsey, R. King, S. C. Baral, B. R. Bhatta, and J. N. Newell, “Development of a Patient-Centred, Psychosocial Support Intervention for Multi-Drug-Resistant Tuberculosis (MDR-TB) Care in Nepal.,” PLoS One, vol. 12, no. 1, p. e0167559, 2017, doi: 10.1371/journal.pone.0167559.

How to Cite This

Article Metrics

Download Statistics

Downloads

Download data is not yet available.

Other Statistics

Copyright and Permissions

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Publishing your paper with Jurnal Teknologi Kesehatan (Jurtekkes) means that the author or authors retain the copyright in the paper. Jurtekkes granted an exclusive reuse license by the author(s), but the author(s) are able to put the paper onto a website, distribute it to colleagues, give it to students, use it in your thesis etc, even commercially. The author(s) can reuse the figures and tables and other information contained in their paper published by Jurtekkes in future papers or work without having to ask anyone for permission, provided that the figures, tables or other information that is included in the new paper or work properly references the published paper as the source of the figures, tables or other information, and the new paper or work is not direct at private monetary gain or commercial advantage.

Jurtekkes journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge. This journal is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets others remix, transform, and build upon the material for any purpose, even commercially.

Jurtekkes journal Open Access articles are distributed under this Creative Commons Attribution-ShareAlike 4.0 International License (CC BY-SA). Articles can be read and shared for All purposes under the following conditions:

• BY: You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
• SA:  If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.

Data Availability